<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"><channel><title>FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class — Live Feed</title><link>https://www.live-feeds.com/feed/fda-rejects-summit-s-ivonescimab-derailing-us-arrival-of-much-hyped-pd-1xvegf-class</link><atom:link xmlns:atom="http://www.w3.org/2005/Atom" href="https://www.live-feeds.com/feed/fda-rejects-summit-s-ivonescimab-derailing-us-arrival-of-much-hyped-pd-1xvegf-class/rss.xml" rel="self" type="application/rss+xml"/><description>Continuously updated, source-cited coverage.</description>
<item><title>FDA rejects Summit and Akeso's ivonescimab for lung cancer</title><link>https://www.live-feeds.com/feed/fda-rejects-summit-s-ivonescimab-derailing-us-arrival-of-much-hyped-pd-1xvegf-class</link><guid isPermaLink="false">https://www.live-feeds.com/feed/fda-rejects-summit-s-ivonescimab-derailing-us-arrival-of-much-hyped-pd-1xvegf-class#u207584</guid><pubDate>Wed, 18 Nov 2026 21:05:28 +0000</pubDate><description>The U.S. Food and Drug Administration has declined to approve ivonescimab, a PD-1xVEGF bispecific antibody developed by Summit Therapeutics and Akeso, for non-small cell lung cancer. The rejection follows the drug&amp;#039;s failure to meet a key survival goal in a pivotal trial. The decision blocks the U.S. introduction of this China-originated class and represents a setback for Summit&amp;#039;s commercial plans and China&amp;#039;s biotech sector ambitions. The FDA has published its rejection letter outlining multiple issues with the application.Why it mattersIvonescimab was viewed as a leading candida</description></item>
</channel></rss>